CCM
APLS

Consonance Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Consonance Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$327K – 29
2020
Q2 		$327K Hold
10,000
– – 0.02% 31
2020
Q1 		$268K Sell
10,000
-125,000
-93% -$4.44M 0.02% 31
2019
Q4 		$4.13M Buy
+135,000
New +$3.74M 0.25% 34

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Consonance Capital Management's APLS Position: Q3 2020 in Review

Consonance Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2020, closing a stake of 10,000 shares — an estimated $327K sold.

Consonance Capital Management first reported a position in APLS in Q4 2019 and held it in 3 quarters. The position peaked at $4.13M in Q4 2019. 145 funds tracked by Wall St. Rank hold APLS as of Q3 2020.

  • Consonance Capital Management reported no remaining Apellis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Consonance Capital Management sold 10,000 Apellis Pharmaceuticals shares in Q3 2020, an estimated $327K.
  • Consonance Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Consonance Capital Management's Apellis Pharmaceuticals position peaked at $4.13M in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2020.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.